AbCellera Biologics Financials - Benzinga

AbCellera Biologics Inc

ABCLNASDAQ

Trade with Public

Trade with Public

$11.44

-0.13-1.12%

Dern. MÀJ: Sep 4, 10:45 AM

Aperçu Actualités Prévisions de résultats Événements Objectifs de coursDonnées financièresSentiment Actionnariat Comparer Options Rapport sur les stocks

AbCellera Biologics Financials

AbCellera Biologics (ABCL) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
AbCellera Biologics Q2 EPS $(0.18) Misses $(0.14) Estimate, Sales $4.050M Miss $7.784M Estimate

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 50 percent decrease over losses of $(0.12) per share

Benzinga Newsdesk

PRO
AbCellera Biologics Q1 EPS $(0.14) Beats $(0.20) Estimate, Sales $8.315M Beat $5.856M Estimate

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is unchanged from the same period last year. The company reported

Benzinga Newsdesk

Earnings Scheduled For May 11, 2026

Benzinga Insights

What Sparked AbCellera Biologics To Soar Over 9% After Hours

AbCellera Biologics shares jumped 9.3% after hours to $3.52 following an 83% earnings beat in Q4 2025.

Mohd Haider

AbCellera Biologics Q4 Earnings Report: What Investors Need to Know

Benzinga Insights

PRO
AbCellera Biologics Q4 EPS $(0.03) Beats $(0.17) Estimate, Sales $44.900M Beat $6.351M Estimate

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.17) by 82.04 percent. This is a 75 percent increase over losses of $(0.12) per share from

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved